<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27900" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Protriptyline</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saef</surname>
            <given-names>Moadh A.</given-names>
          </name>
          <aff>Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yilanli</surname>
            <given-names>Musa</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Moadh Saef declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Musa Yilanli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27900.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Protriptyline hydrochloride is a tricyclic antidepressant used to improve mood in people with depression. It is also useful in treating anxiety. It is a more potent antidepressant and has fewer sedative and tranquilizing effects than other TCAs. FDA-approved uses include mental depression, narcolepsy, attention deficit hyperactivity disorder, and headaches. It also has other non-FDA approved indications. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of protriptyline, so providers can direct patient therapy in treating conditions for which it is indicated, as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of protriptyline.</p></list-item><list-item><p>Review the approved and off-label indications for initiating protriptyline therapy.</p></list-item><list-item><p>Describe the adverse event profile and contraindications of protriptyline.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance protriptyline and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27900&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27900">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27900.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Protriptyline hydrochloride is a tricyclic antidepressant used to improve mood in people with depression. It is also used for anxiety. Protriptyline was first patented in 1962, and it is sold under many brand names. It is an amine with the empirical formula of CHN. It is a more potent antidepressant and has&#x000a0;fewer sedative and tranquilizing effects than other TCAs.</p>
        <p>
<bold>FDA-Approved Uses</bold>
<xref ref-type="bibr" rid="article-27900.r1">[1]</xref>
<xref ref-type="bibr" rid="article-27900.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mental depression</p>
          </list-item>
          <list-item>
            <p>Narcolepsy</p>
          </list-item>
          <list-item>
            <p>Attention deficit hyperactivity disorder</p>
          </list-item>
          <list-item>
            <p>Headaches</p>
          </list-item>
        </list>
        <p>Results of one study of 25 women who were treated with 20 mg of protriptyline each morning for 12 weeks showed 86% fewer headaches each month, with an average dropping from 28.2 to 11.7 days<xref ref-type="bibr" rid="article-27900.r3">[3]</xref>. More than&#x000a0;two-thirds had a 50% reduction in the number of headaches per month. The study also showed an average of 1 pound (0/45 kg) per month of weight loss.</p>
        <p>
<bold>Non-FDA-Approved Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-resistant depression</p>
          </list-item>
          <list-item>
            <p>Local anesthetic</p>
          </list-item>
          <list-item>
            <p>Smoking cessation</p>
          </list-item>
          <list-item>
            <p>Cocaine dependence</p>
          </list-item>
          <list-item>
            <p>Apnea</p>
          </list-item>
        </list>
        <p>One study reported that protriptyline could be helpful in brain-injured adults with attention and behavioral difficulties.<xref ref-type="bibr" rid="article-27900.r4">[4]</xref><xref ref-type="bibr" rid="article-27900.r1">[1]</xref>&#x000a0;Research has also shown it to improve the drowsiness, apneic episodes, snoring, and cataplexy related to narcolepsy.<xref ref-type="bibr" rid="article-27900.r5">[5]</xref></p>
      </sec>
      <sec id="article-27900.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>When it comes to mood, the two important chemicals in the brain are serotonin and norepinephrine. These often decrease in people who are depressed and are the main targets of antidepressants. Protriptyline has the fastest onset of action among other tricyclic antidepressants, and thus clinical effects can occur within the first week of use. It is a secondary tricyclic amine and structurally similar to nortriptyline. It undergoes limited first-pass hepatic metabolism and can cross the blood-brain barrier. Protriptyline has a long half-life of 80 to 200 hours when used long-term, requiring up to a month to reach a steady state. The half-life of protriptyline is approximately 74 hours (greater than three days).</p>
        <list list-type="bullet">
          <list-item>
            <p>Increases norepinephrine neurotransmission by blocking norepinephrine reuptake pump.</p>
          </list-item>
          <list-item>
            <p>In the frontal cortex, dopamine neurotransmission increases secondary to the norepinephrine reuptake inhibition.<xref ref-type="bibr" rid="article-27900.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>At high doses, protriptyline can increase serotonin neurotransmission.</p>
          </list-item>
          <list-item>
            <p>Protriptyline also can cause calcium-independent cell death.<xref ref-type="bibr" rid="article-27900.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27900.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Unlike other tricyclic or tetracyclic antidepressants, which have doses from 75 to 300 mg/day, protriptyline dosing uses much lower doses and then increased as necessary. Unlike other tricyclic and tetracyclic drugs, which often have once a day dosing, dosage for protriptyline is divided into 3 or 4 times a day. When stopping the medication is necessary, taper to avoid the effects of withdrawal.</p>
        <list list-type="bullet">
          <list-item>
            <p>Protriptyline is available in tablets of 5 or 10 mg.</p>
          </list-item>
          <list-item>
            <p>Initiate at 15 to 40 mg a day, starting with the morning dose.</p>
          </list-item>
          <list-item>
            <p>Divide dose into 3 or 4 doses, not to be taken all at one time.</p>
          </list-item>
        </list>
        <p>The maximum dose is 60 mg a day, if necessary, beginning at a lower level and increasing gradually while looking for the patient&#x02019;s response and any side effects as the dosage increase.&#x000a0;</p>
      </sec>
      <sec id="article-27900.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Protriptyline, like all TCAs, has multiple adverse effects. Although as effective as SSRIs and SNRIs, TCAs, and MAOs are not first-line treatment due to their side effects. Among the TCAs, protriptyline is the most likely to cause tachycardia, hypotension, anxiety, and agitation, and for this reason, some European countries have discontinued protriptyline use.<xref ref-type="bibr" rid="article-27900.r7">[7]</xref><xref ref-type="bibr" rid="article-27900.r8">[8]</xref><xref ref-type="bibr" rid="article-27900.r2">[2]</xref><xref ref-type="bibr" rid="article-27900.r9">[9]</xref></p>
        <p>
<bold>Adverse Effects (like&#x000a0;all TCAs)&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS depression</p>
          </list-item>
          <list-item>
            <p>Convulsions</p>
          </list-item>
          <list-item>
            <p>Cardiac toxicity</p>
          </list-item>
          <list-item>
            <p>Weight gain</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
        </list>
        <p>
<bold>Most Common Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Apathy</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Restlessness</p>
          </list-item>
          <list-item>
            <p>Insomnia (decrease of REM sleep)</p>
          </list-item>
          <list-item>
            <p>Nightmares</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Hyponatremia</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Itching</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Dry mouth Impotence</p>
          </list-item>
          <list-item>
            <p>Change of libido</p>
          </list-item>
          <list-item>
            <p>Impotence</p>
          </list-item>
          <list-item>
            <p>Difficulty having an orgasm</p>
          </list-item>
          <list-item>
            <p>Suicidal thoughts and suicide attempts (black box warning) and risk, especially in that younger than 24 years old, is greater during the initial two months of starting the drug and during dosage adjustment.</p>
          </list-item>
        </list>
        <p>
<bold>Rare, More Serious Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic failure</p>
          </list-item>
          <list-item>
            <p>Increased intraocular pressure</p>
          </list-item>
          <list-item>
            <p>Induction of mania</p>
          </list-item>
          <list-item>
            <p>Paralytic ileus</p>
          </list-item>
          <list-item>
            <p>Extrapyramidal symptoms</p>
          </list-item>
          <list-item>
            <p>QTc prolongation, arrhythmia, tachycardia, myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Stroke, seizures, coma</p>
          </list-item>
          <list-item>
            <p>Sudden death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27900.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Tricyclic antidepressants have many side effects, some of which are life-threatening. Among the tricyclic antidepressants, protriptyline is the most potent and most likely to cause hypotension, agitation, and cardiac effects. For this reason, protriptyline has multiple contraindications, including people with the following <xref ref-type="bibr" rid="article-27900.r7">[7]</xref><xref ref-type="bibr" rid="article-27900.r9">[9]</xref><xref ref-type="bibr" rid="article-27900.r8">[8]</xref><xref ref-type="bibr" rid="article-27900.r9">[9]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart problems such as prolonged QTC interval, uncompensated heart failure, arrhythmias, heart block, palpitations, hypotension, hypertension, and recent myocardial infarction.</p>
          </list-item>
          <list-item>
            <p>Use of drugs that inhibit TCA metabolism, inhibit CYP450 2D6, or prolong QTc interval. (Look for hypokalemia before starting protriptyline.)</p>
          </list-item>
          <list-item>
            <p>Use of tramadol (increase the risk of seizures with TCAs), and people with a seizure disorder require careful monitoring.</p>
          </list-item>
          <list-item>
            <p>Use of anticholinergic drugs (risk of hyperthermia and paralytic ileus).</p>
          </list-item>
          <list-item>
            <p>Use of SSRIs, SNRIs, and MAOIs to prevent serotonin syndrome, hypertensive crisis or hypotensive crisis, hyper-pyretic, and convulsions, a washout period of at least 14 days must take effect before starting one of these drugs.</p>
          </list-item>
          <list-item>
            <p>Weight gain concerns and/or metabolic syndrome.</p>
          </list-item>
          <list-item>
            <p>Psychosis due to TCAs aggravating psychotic symptoms</p>
          </list-item>
          <list-item>
            <p>Possible pregnancy or&#x000a0;women who are breastfeeding (due to potential adverse effects to the fetus such as fetal malformations, lethargy, and withdrawal symptoms. protriptyline is classified in pregnancy category C)</p>
          </list-item>
          <list-item>
            <p>Age younger than 12 due to the increased risk of suicidal thoughts/suicidal attempts in children</p>
          </list-item>
          <list-item>
            <p>History of hypersensitivity to protriptyline</p>
          </list-item>
          <list-item>
            <p>Hyperthyroidism, urinary retention, and angle-closure glaucoma merit closer monitoring.</p>
          </list-item>
          <list-item>
            <p>Renal or hepatic impairment may need to lower dose and may need to monitor closely.</p>
          </list-item>
          <list-item>
            <p>Consumption of alcohol should also be avoided due to the additive CNS effects.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27900.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Protriptyline&#x02019;s initial dose is 15 mg per day divided into 3 or 4 doses per day, with a max dose of 60 mg per day. However, taking more than recommended or taking the daily dose at one time can have significant consequences which can manifest&#x000a0;in cardiac arrhythmias or EKG changes, especially QRS-widening hypotension, confusion, visual hallucinations, delusions, ataxia, tremors, syndrome of inappropriate ADH, tinnitus, hyperactive reflexes, muscle rigidity stupor, convulsions, coma, and even death.<xref ref-type="bibr" rid="article-27900.r2">[2]</xref><xref ref-type="bibr" rid="article-27900.r7">[7]</xref></p>
        <p>ECG is a recommendation and close monitoring for patients over the age of 50, especially in those taking more than 20 mg per day, due to sensitivity to anticholinergic, cardiovascular, hypotensive, and sedative effects.</p>
        <p>Like other antidepressants, protriptyline increases suicidal ideation and attempts in children, adolescents, and young adults. It is not recommended in patients under the age of 12&#x000a0;or intended for those under the age of 6.</p>
      </sec>
      <sec id="article-27900.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Tricyclic antidepressants, like all antidepressants, are used in a group of patients that are already at increased risk of attempted suicide. Thus, overdose with such drugs is something that needs to have a plan at hand. Furthermore, TCAs are often used in drug-resistant depression, which makes them even more of a risk than the first-line SSRIs and SNRIs. Thus protriptyline is a very potent TCA&#x000a0;and a dangerous drug&#x000a0;for overdose.</p>
        <p>Treatment of protriptyline toxicity includes gastrointestinal decontamination with gastric lavage and activated charcoal l and treating the symptoms that arise due to the overdose as necessary; for example, norepinephrine and IV fluids for hypotension, IV sodium bicarbonate for prolonged QRS duration, and benzodiazepines for anxiety, agitation, or seizures.</p>
      </sec>
      <sec id="article-27900.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Protriptyline is an older tricyclic antidepressant which has little use today. Healthcare workers, including the pharmacist and prescribing nurse, should be familiar with newer antidepressants, which are much safer. Patients already on protriptyline should be gradually weaned off and started on the newer antidepressants if there are no contraindications.</p>
      </sec>
      <sec id="article-27900.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27900&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27900">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27900/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27900">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27900.s11">
        <title>References</title>
        <ref id="article-27900.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilens</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Biederman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abrantes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1485</fpage>
            <page-range>1485-90</page-range>
            <pub-id pub-id-type="pmid">8936915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furukawa</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review.</article-title>
            <source>BMJ</source>
            <year>2002</year>
            <month>Nov</month>
            <day>02</day>
            <volume>325</volume>
            <issue>7371</issue>
            <fpage>991</fpage>
            <pub-id pub-id-type="pmid">12411354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Protriptyline, chronic tension-type headaches, and weight loss in women.</article-title>
            <source>Headache</source>
            <year>1997</year>
            <season>Jul-Aug</season>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>433</fpage>
            <page-range>433-6</page-range>
            <pub-id pub-id-type="pmid">9277026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansode</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Jana</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Batkulwar</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Warkad</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sengupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>e105196</fpage>
            <pub-id pub-id-type="pmid">25141174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Quinnell</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapies for obstructive sleep apnoea: where are we now?</article-title>
            <source>Drugs</source>
            <year>2004</year>
            <volume>64</volume>
            <issue>13</issue>
            <fpage>1385</fpage>
            <page-range>1385-99</page-range>
            <pub-id pub-id-type="pmid">15212557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Shieh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Protriptyline on [Ca&#x000b2;&#x0207a;]i and Viability in MDCK Renal Tubular Cells.</article-title>
            <source>Chin J Physiol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>30</day>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-123</page-range>
            <pub-id pub-id-type="pmid">28468029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elonen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mattila</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Saarnivaara</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of amitriptyline, nortriptyline, protriptyline and doxepin in conscious rabbits.</article-title>
            <source>Eur J Pharmacol</source>
            <year>1974</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>178</fpage>
            <page-range>178-88</page-range>
            <pub-id pub-id-type="pmid">4430320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Meta-analytical studies on new antidepressants.</article-title>
            <source>Br Med Bull</source>
            <year>2001</year>
            <volume>57</volume>
            <fpage>161</fpage>
            <page-range>161-78</page-range>
            <pub-id pub-id-type="pmid">11719915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27900.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elonen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mattila</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of amitriptyline, nortriptyline, protriptyline, and doxepin in conscious rabbits after subacute pretreatment with protriptyline.</article-title>
            <source>Med Biol</source>
            <year>1975</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>238</fpage>
            <page-range>238-44</page-range>
            <pub-id pub-id-type="pmid">1186320</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
